In the current report, we have demonstrated in three independent institutional cohorts that IHC-based detection of cytoplasmic TRMT2A identifies a subset of HER2+ patients with a high likelihood of recurrence.
Based on these data, the 2.5-mg twice-daily dose was approved in Europe as an adjunct to antiplatelet therapy, but only in patients with a recent ACS event and elevated cardiac biomarkers, suggesting a high likelihood of recurrence.
9 SAC 1 and 2 events are defined as those that have incurred either severe or major consequences to the patient with any likelihood of recurrence, or an event that has incurred moderate consequences with at least a moderate likelihood of recurrence.
As regards T and N stage, we observed a higher likelihood of recurrence for advanced tumours, even if this tendency was not statistically significant.
As discussed briefly above, some suggest that patients with a prior history of high dose radiation are more likely to present with higher grade lesions and have a greater likelihood of recurrence [ 3– 5, 11, 29, 30, 34, 36– 36].
Targeting the androgen pathway in the preoperative period may provide an opportunity to improve oncologic outcomes for patients who present with high-risk disease and therefore have a higher likelihood of recurrence.
Glioblastoma multiforme (GBM, WHO grade IV) is the most common and lethal primary malignant brain tumour that continues to have poor prognosis and a high likelihood of recurrence [ 1].
HER2 amplification in primary mucinous carcinomas was not associated with an increased likelihood of recurrence.
The activity of c-Src kinase might therefore be associated with an increased likelihood of recurrence in LBC.
Log odds ratios were calculated for each pair of tumours as a measurement of likelihood of recurrence using methylation data.
Yin reported that in multivariate analysis, TNBC had a significantly increased likelihood of recurrence within 2 years after surgery rather than thereafter [ 4].
